Dr. Keith Allen MD
Director, Cardiothoracic Vascular Surgery Research, Mid America Heart & Lung Surgeons, PC
Member of the Healthcare Council
Council Member Biography
Keith Allen, MD, is a Director of Cardiothoracic-Vascular Surgery Research at the Mid America Heart Institute in Kansas City, Missouri. He is board certified in Thoracic, Vascular, and General Surgery. Dr. Allen maintains an active clinical research department and has over 100 publications in journals such as the NEJM, JTCVS, and The Annals of Thoracic Surgery. He is serving on the FDA's Circulatory Device Panel. Additionally, Dr. Allen continues to advise companies on clinical study design, Medicare reimbursement issues, and FDA regulatory process including two successful PMA presentations to the FDA device panel as the lead presenter. He is a Fellow of the American College of Surgeons and a member of American Association of Thoracic Surgeons (AATS), Society of Thoracic Surgery (STS), and the International Society for Minimally Invasive Surgery (ISMICS). (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Director, Cardiothoracic Vascular Surgery Research, Mid America Heart & Lung Surgeons, PC
- 1994 - 2007
- Surgeon, CORVASC MD'S PC
GLG NewsSM Analyses by Keith Allen
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Drug Eluting Stents:The Next Vioxx
December 14, 2006
Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org
1. DES whether used on or off label will likely require life long anticoagulation with Plavix like drugs.
2. The incidence of late thrombosis is significant when anticoagulation is interrupted for events such as elective surgery.
3. Unlike restenosis following insertion of a bare metal stent which rarely results in death to the patient, late thrombosis following use of a DES results in a 50% mortality.
4. Hints of this problem were present during FDA presentations prior to DES approval which may lead to significant liability as this problem becomes more apparent.
GLG Study Groups with Keith Allen(?)
| Study Group Name | No. Members |
|---|---|
| Heart Failure Specialists (US) | 1083 |
| Physicians who Treat Hypertension (US) | 949 |
| Medical Device Experts | 513 |
| Physicians in the U.S. who Treat Chronic Obstructive Pulmonary Disease (COPD) | 447 |
| Physicians who Treat Peripheral Vascular Disease | 340 |
GLG Live Meetings with Keith Allen(?)
Keith Allen has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.